HC Wainwright Has Bullish Outlook for PepGen FY2027 Earnings

PepGen, Inc. (NASDAQ:PEPG) – Equities research analysts at HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for PepGen in a report issued on Friday, August 7th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($1.78) per share for the year, up from their prior forecast of ($1.79). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for PepGen’s current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for PepGen’s FY2029 earnings at ($1.33) EPS.

Several other equities analysts also recently issued reports on the stock. Craig Hallum initiated coverage on shares of PepGen in a report on Tuesday, June 16th. They set a “buy” rating and a $11.00 price objective on the stock. Weiss Ratings cut shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. Wall Street Zen upgraded shares of PepGen from a “sell” rating to a “hold” rating in a research report on Sunday, June 7th. Finally, Wedbush decreased their price target on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, PepGen presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

PepGen Stock Performance

Shares of NASDAQ PEPG opened at $2.99 on Tuesday. The firm has a market cap of $207.09 million, a PE ratio of -2.28 and a beta of 1.89. The firm has a fifty day moving average of $1.89 and a 200 day moving average of $3.09. PepGen has a one year low of $1.01 and a one year high of $7.80.

PepGen (NASDAQ:PEPG) last announced its earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02.

Institutional Trading of PepGen

Several large investors have recently bought and sold shares of PEPG. AQR Capital Management LLC acquired a new stake in PepGen in the 1st quarter valued at about $122,000. Woodline Partners LP purchased a new position in PepGen in the 1st quarter worth approximately $1,097,000. Marshall Wace LLP acquired a new position in shares of PepGen during the 2nd quarter worth approximately $44,000. Qube Research & Technologies Ltd acquired a new position in shares of PepGen during the 2nd quarter worth approximately $81,000. Finally, Bridgeway Capital Management LLC grew its position in shares of PepGen by 61.5% in the second quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock valued at $102,000 after purchasing an additional 35,000 shares in the last quarter. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).